Lysosomal TMEM9-LAMTOR4-controlled MTOR Signaling Integrity is Required for Mammary Tumorigenesis

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2022 Nov 7

PMID 36336962

Authors

Shengzhe Zhang

Sung Ho Lee

Litong Nie

Yuanjian Huang

Gengyi Zou

Youn-Sang Jung

Sohee Jun

Jie Zhang

Esther M Lien

Junjie Chen

Jae-Il Park

Affiliations

Soon will be listed here.

Citing Articles

Comprehensive analysis of TMEM9 in human tumors.

Zhang X, Zhou L, Wei S, Zhang X Discov Oncol. 2025; 16(1):276.

PMID: 40053281 PMC: 11889325. DOI: 10.1007/s12672-025-02040-1.

Elevated LAMTOR4 Expression Is Associated with Lethal Prostate Cancer and Its Knockdown Decreases Cell Proliferation, Invasion, and Migration In Vitro.

Gamallat Y, Alwazan H, Turko R, Dang V, Seyedi S, Ghosh S Int J Mol Sci. 2024; 25(15).

PMID: 39125671 PMC: 11312415. DOI: 10.3390/ijms25158100.

Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.

Gao H, Wei L, Indulkar S, Nguyen T, Liu D, Ho M Breast Cancer Res. 2024; 26(1):111.

PMID: 38965614 PMC: 11225427. DOI: 10.1186/s13058-024-01861-2.

TMEM9 promotes lung adenocarcinoma progression via activating the MEK/ERK/STAT3 pathway to induce VEGF expression.

Wang Z, Zhao P, Tian K, Qiao Z, Dong H, Li J Cell Death Dis. 2024; 15(4):295.

PMID: 38664392 PMC: 11045738. DOI: 10.1038/s41419-024-06669-8.

Molecular subtype identification and prognosis stratification based on lysosome-related genes in breast cancer.

Liu X, Sun K, Yang H, Zou D, Xia L, Lu K Heliyon. 2024; 10(4):e25643.

PMID: 38420434 PMC: 10900431. DOI: 10.1016/j.heliyon.2024.e25643.

References

Zou Z, Tao T, Li H, Zhu X . mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020; 10:31. PMC: 7063815. DOI: 10.1186/s13578-020-00396-1. View

Jung Y, Stratton S, Lee S, Kim M, Jun S, Zhang J . TMEM9-v-ATPase Activates Wnt/β-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis. Hepatology. 2020; 73(2):776-794. PMC: 7647947. DOI: 10.1002/hep.31305. View

Caro-Vegas C, Bailey A, Bigi R, Damania B, Dittmer D . Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma. mBio. 2019; 10(1). PMC: 6381283. DOI: 10.1128/mBio.02871-18. View

Kuroshima K, Yoshino H, Okamura S, Tsuruda M, Osako Y, Sakaguchi T . Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. Cancer Sci. 2020; 111(5):1607-1618. PMC: 7226215. DOI: 10.1111/cas.14395. View

Chresta C, Davies B, Hickson I, Harding T, Cosulich S, Critchlow S . AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2009; 70(1):288-98. DOI: 10.1158/0008-5472.CAN-09-1751. View